Microtitration of Rubella Virus in Monovalent Vaccinal Products

• Main Authors: F Esna-Ashari (Author), A Shafyi (Author), M Taqavian (Author), A Mohammadi (Author), ZA Sadigh (Author), GhH Sabiri (Author), H Mirshahreza (Author), Z Hamzehloo (Author), F Taleblue (Author), N Sheikh-Mohammadi (Author)
• Format: Book
• Published: Tehran University of Medical Sciences, 2011-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2251-6085; 2251-6093
• Keywords: Microtitration; Rubella virus; Potency test; Microplate; Public aspects of medicine; RA1-1270
• Source: Iranian Journal of Public Health, Vol 40, Iss 1 (2011)

Background: Potency test for control of rubella vaccine is a significant factor to qualify production line and vaccination pro­gram. For this reason, WHO recommends to use the microtitration method by both vaccine companies and control laborato­ries. Then the study was done to improve this test. Methods: Three rubella virus samples, including an in-house standard, a lot of vaccine and an in- process product, were tit­tered in cell culture tubes. Then micro titration steps were tested on 96-well microplate using cocultivation of standard ru­bella vaccine dilutions and RK- 13 cell line. After 6-7 days, final reading was done and calculated the titer. Two other sam­ples were assayed with the micromethod. Results: Titer reduction less than 0.5 log was acquired for each sample during frequent tests and between two methods. Conclusion: The procedure was profitable and accurate for potency and identity tests of rubella virus vaccine, on the basis of WHO recommendations.